You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
New method for immunoprofiling of the tumor microenvironment of cancer patients by opal multiplex quantitative immunofluorescence (IF) assay
  1. Nikoletta L Kallinteris1,
  2. Joseph Shan1,
  3. Jeffrey Meyer2,
  4. Adam C Yopp3,
  5. Athur Frankel4,
  6. Sean R Downing5,
  7. Brenda S Robertson5,
  8. Cliff Hoyt5,
  9. Steven King1,
  10. Carlo Bifulco6,7,
  11. Carmen Ballesteros-Merino6,7 and
  12. Bernard Fox6,7,8
  1. Aff1 grid.430202.7Peregrine Pharmaceuticals Tustin CA USA
  2. Aff2 grid.267313.20000000094827121Department of Internal Medicine and Medical OncologyUT Southwestern Medical Center Dallas TX USA
  3. Aff3 grid.267313.20000000094827121Department of Surgery, Division of Surgical OncologyUT Southwestern Medical Center Dallas TX USA
  4. Aff4 grid.267313.20000000094827121Department of Hematology OncologyUT Southwestern Medical Center Dallas TX USA
  5. Aff5 grid.419236.b0000 0001 2176 1341PerkinElmer Hopkinton MA USA
  6. Aff6 grid.415286.c0000 0004 0463 5556Earle A. Chiles Research Institute Portland OR USA
  7. Aff7 grid.415337.7Providence Cancer Center Portland OR USA
  8. Aff8 Robert W. Franz Cancer Research Center Portland OR USA

http://dx.doi.org/10.1186/2051-1426-3-S2-P94

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Bavituximab is a novel chimeric IgG1 monoclonal antibody targeting the membrane phospholipid, phosphatidylserine (PS), externalized on the luminal surface of endothelium in tumors, tumor cells, and tumor exosomes under stressor conditions in the tumor microenvironment. PS exposure on tumor vessels is increased by chemotherapy and irradiation, thereby amplifying the target for bavituximab. The purpose of this investigation was to develop OpalTM 6-plex quantitative immunofluorescence (IF) assays ImmunoProfiling the tumor microenvironment of rectal adenocarcinoma (seven), hepatocellular carcinoma (HCC) (six), and advanced melanoma (two) patients treated with bavituximab combination treatments and to identify biomarkers that correlate immune response to patient survival.

    Methods

    OpalTM 6-plex quantitative IF assays utilizing Vectra Imaging System with inForm software were developed to evaluate the presence of immune infiltrates in pre- and post-treatment biopsies, or residual surgery specimen obtained from consented patients in three investigator-sponsored clinical trials with UTSW IRB approval. Formalin fixed paraffin embedded samples of patients primary tumor and post treatment, or residual surgery specimen were immuno stained with i) panel of lymphoid cell markers for CD4, CD8, PD-1, FoxP3, GranzymeB, IL-2 and DAPI, ii) panel of myeloid cell markers for CD68, iNOS, Arg-1, CD31, CD33, CD14 and DAPI, iii) panel of dendritic cell markers for PD-L1, CD11c, CD80, CD86, HLA-DR, PS, and DAPI with same species fluorescence primary antibodies labeling without cross-reactivity using tyramide signal amplification. These custom-designed assays allow single cell coexpression of multiple biomarkers in the same tissue section and can be used to quantify specific immune cells infiltration and immunomodulation of the tumor microenvironment mediated by bavituximab.

    Results

    Preliminary results demonstrate reliable detection, quantification, and phenotyping of lymphocytes and monocytes present in tumor tissues obtained from consented rectal adenocarcinoma, HCC, and advanced melanoma patients treated with bavituximab combination therapies.

    Conclusions

    OpalTM 6-plex quantitative IF assays present a unique capability and read out assay for elucidating immunomodulation of macrophages and dendritic cells mediated by bavituximab.

    Written informed consent (ICF) was obtained from all patients to collect biopsies for exploratory biomarkers research and for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the editor of this journal.